Impact of price deregulation policy on the affordability of essential medicines for women’s health: a panel data analysis

References

• Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–1484.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Health Observatory (GHO) Data. Geneva: World Health Organization. 2016.
   Google Scholar
• Gronowski AM, Schindler EI. Women’s Health INTRODUCTION. Scand J Clin Lab Investig. 2014;74:2–7.
   Web of Science ®Google Scholar
• Stephens P, Ross-Degnan D, Wagner AK. Does access to medicines differ by gender? Evidence from 15 low and middle income countries. Health Policy. 2013;110(1):60–66.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Health Topics: essential Medicines. Geneva: World Health Organization. 2016.
   Google Scholar
• Hill S, Yang AN, Bero L. Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One. 2012;7(5):6.
   Web of Science ®Google Scholar
• World Health Organization. Priority medicines for mothers and children. Geneva: World Health Organization. 2011.
   Google Scholar
• Spinks J, Chen G, Donovan L. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy. Aust Health Rev. 2013;37(5):675–681.
   PubMed Web of Science ®Google Scholar
• Brekke KR, Holmas TH, Rune Straume O. Reference pricing, competition, and pharmaceutical expenditures: theory and evidence from a natural experiment. J Public Econ. 2011;95(7–8):624–638.
   Web of Science ®Google Scholar
• Kwon H-Y, Kim H, Godman B, et al. The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):1007–1014.
   PubMed Web of Science ®Google Scholar
• Font JC. Deregulation and access to medicines: the peruvian experience. J Int Dev. 2016;28(6):997–1005.
   Web of Science ®Google Scholar
• Maiga D, Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health Policy. 2010;97(2–3):130–135.
   PubMed Web of Science ®Google Scholar
• Peltzman S. The economic theory of regulation after a decade of deregulation. Brookings Pap Econ Act. 1989:1. Ed.^(Eds). 1989;1(2):1-59.
   Web of Science ®Google Scholar
• Prayle D, Brazier M. Supply of medicines: paternalism, autonomy and reality. J Med Ethics. 1998;24(2):93–98.
   PubMed Web of Science ®Google Scholar
• Hu J, Mossialos E. Pharmaceutical pricing and reimbursement in China: when the whole is less than the sum of its parts. Health Policy. 2016;120(5):519–534.
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy. 2011;101(2):146–152.
   PubMed Web of Science ®Google Scholar
• Hu S. Essential medicine policy in China: pros and cons. J Med Econ. 2013;16(2):289–294.
   PubMedGoogle Scholar
• Carradinha H. Tendering short-term pricing policies and the impact on patients, governments and the sustainability of the generic medicines industry. J Generic Med. 2009;6(9):351–361.
   Google Scholar
• State Council Development Research Center. Development research center joint seminars. Beijing: State Council Development Research Center. 2015.
   Google Scholar
• Chinese Medical Association. Chinese medical doctor association. model procurement list of off-patent medicines for women’s health. China: Chinese Medical Association. 2015.
   Google Scholar
• Statistics Bureau of Hubei Province. Statistical bulletin. Hubei: Statistics Bureau of Hubei Province. 2016.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC: structure and Principles. Norway: WHO Collaborating Centre for Drug Statistics Methodology. 2011.
   Google Scholar
• WHO collaborating centre for drug statistics methodology. ATC/DDD Index. Norway: WHO collaborating centre for drug statistics methodology. 2016. (Ed.^(Eds).
   Google Scholar
• Eichler H-G, Hurts H, Broich K, et al. Drug regulation and pricing - can regulators influence affordability? New England J Med. 1807-1809;374(19):2016.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. DDD: definition and general considerations. Norway: WHO Collaborating Centre for Drug Statistics Methodology. 2016.
   Google Scholar
• Stargardt T. Modelling pharmaceutical price changes in Germany: a function of competition and regulation. Appl Econ. 2011;43(29):4515–4526.
   Web of Science ®Google Scholar
• Danzon PM, Chao LW. Does regulation drive out competition in pharmaceutical markets? J Law Econ. 2000;43(2):311–357.
   Web of Science ®Google Scholar
• Zhao M, Wu J. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance. Expert Rev Pharmacoecon Outcomes Res. 2016;1-10.
   Google Scholar
• Hostenkamp G. Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector. Health Policy. 2013;111(1):68–77.
   PubMed Web of Science ®Google Scholar
• Croissant Y, Millo G. Panel data econometrics in R: the plum package. J Stat Softw. 2008;27(2):1–43.
   Web of Science ®Google Scholar
• Reiffen D, Ward MR. Generic drug industry dynamics. Rev Econ Stat. 2005;87(1):37–49.
   Web of Science ®Google Scholar
• Aalto-Setala V, Alaranta A. Effect of deregulation on the prices of nicotine replacement therapy products in Finland. Health Policy. 2008;86(2–3):355–362.
   PubMed Web of Science ®Google Scholar
• Wu J, Xu J, Liu G, et al. Pharmaceutical pricing: an empirical study of market competition in chinese hospitals. Pharmacoeconomics. 2014;32(3):293–303.
   PubMed Web of Science ®Google Scholar
• Manova M, Stoimenova A, Savova A, et al. Utilization and price trends in some reimbursed cardiovascular medicines. Biotechnol Equip. 2011;25(2):2424–2431.
   Web of Science ®Google Scholar
• Manova M, Stoimenova A, Clerfeuille F, et al. Impact of generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market. J Public Health. 2011;19(1):91–100.
   Google Scholar
• Wang YR. Price competition in the Chinese pharmaceutical market. Int J Health Care Finance Econ. 2006;6(2):119–129.
   PubMedGoogle Scholar
• Alexander D, Flynn J, Linlins L. Estimates of the demand for ethical pharmaceutical drugs across countries and time. Appl Econiomics. 1994;26(8):821–826.
   Web of Science ®Google Scholar
• Wu X, Zheng Q. Impact on drug quality by change of API sourcing. Chin J New Drugs. 2014;23(12):1382–1389.
   Google Scholar
• Iacocca K, Sawhill J, Zhao Y. A multiple regression model to explain the cost of brand-drugs. Socioecon Plann Sci. 2013;47(3):238–246.
   Web of Science ®Google Scholar
• Chen Q. Advanced econometrics and the use of stata. Beijing: Higher Education Press; 2014.
   Google Scholar